KaloBios terminates Shkreli as CEO
[BENGALURU] Drugmaker KaloBios Pharmaceuticals Inc said it terminated Martin Shkreli as chief executive on Dec 17, the day he was arrested on charges of securities fraud.
Shkreli, who stepped down as CEO of private drugmaker Turing Pharmaceuticals Inc, also resigned from his position on KaloBios' board of directors.
Shkreli was arrested for engaging in what US prosecutors said was a Ponzi-like scheme at his former hedge fund and a pharmaceutical company he previously headed.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Abbott beats quarterly profit estimates on strong medical device sales
Adidas shares surpass two-year high as 'terrace' sneaker trend boosts brand heat
LVMH’s first quarter sales growth slips to 3% on luxury slowdown
US Justice Department to file antitrust suit against Live Nation: WSJ
EU set to launch China probe on medical device procurement
Muji bets its minimalist retail will work for homes, hotels